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Background
Needle-free delivery has the potential to enhance vac-
cine efficacy and safety, as well as facilitate cost-effective
global vaccine distribution and storage. To this end,
microneedle arrays provide the ability for pain-free, safe,
and convenient materials delivery through disruption of
the outer layers of the skin to access potent immune-
competent cell populations residing within the epider-
mal/dermal tissues.
Methods
We have employed this strategy to design a series of
vaccine-delivery strategies based on the rapid delivery of
dried vaccine-containing surface-coatings from biode-
gradable microneedles upon gentle application to the
skin. We have demonstrated the utility of this approach
for the rapid and convenient delivery of plasmid DNA
as well as recombinant adenoviral vectors expressing
model HIV antigens.
Results
When used to deliver a plasmid expressing SIV-Gag
together with poly(I:C) in mice, these engineered micro-
needles elicited stronger cellular and humoral immunity
than traditional naked DNA injections and were compar-
able in potency to DNA administered with in vivo elec-
troporation. Furthermore, microneedle delivery of a
luciferase-expressing plasmid in explanted skin from
Rhesus macaques showed significantly enhanced expres-
sion (~100-fold greater) relative to injected dose-matched
controls. In parallel, we designed coatings to encapsulate
replication-deficient adenoviral vectors, and dried micro-
needle-formulated Ad vaccines were observed to main-
tain biological activity at room temperature for in excess
of 8 weeks, while control formulations rapidly lost
activity within 7 days. Microneedle-delivery of adenoviral
vectors expressing SIV-Gag was observed to produce cel-
lular and humoral immune responses comparable to tra-
ditional intramuscular/intradermal injection. Thus, this
microneedle-based delivery strategy has the potential to
provide enhanced vaccine stability while maintaining effi-
cacy equivalent to traditional approaches.
Conclusion
Together, these results demonstrate the promise of
microneedles for effective and safe vaccine delivery
while showcasing the additional potential for greater sta-
bility in storage and more potent immunogenicity.
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